Australian-US biotech Opthea Ltd has reported disappointing phase 3 results with its lead drug for vision-robbing disease wet age-related macular degeneration (AMD), throwing its future into doubt.

I’ve been involved with the Rebelle Rally since its inception in 2016, either as a competitor or live show host, and over the ...

From European econoboxes such as the all-new Twingo to the AEV-built Prospector XL with an aluminum tray bed, these are our ...

Ionis has committed to a phase 3 programme for its antisense therapy for rare genetic disorder Angelman syndrome, just weeks after Biogen decided against exercising an option to license the drug. The ...

One year after the launch of the Runaki Project - meaning “light” in Kurdish - an ambitious initiative designed to provide 24 ...

The Confederated Tribes of the Colville Reservation in northern Washington state and OATI will install four solar and energy ...